Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41371-020-00409-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sacubitril/Valsartan Role in Patients with Resistant Hypertension: A Systematic Review.
Hellenic J Cardiol
January 2025
Department of Cardiology, Rumah Sakit Umum Daerah Dr. Soedarso, Pontianak, 78124, Indonesia. Electronic address:
Revisiting the place of surgical portal decompression for adults with noncirrhotic portal hypertension due to chronic extrahepatic portal vein obstruction: a scoping review.
HPB (Oxford)
January 2025
Hepato-Biliary Center, AP-HP Paul Brousse Hospital, Paris-Saclay University, INSERM Unit 1193, 94800 Villejuif, France. Electronic address:
Background: Liver cirrhosis accounts for more than 90 % of portal hypertension cases, and the other cases are due to noncirrhotic portal hypertension (NCPH). Variceal bleeding is the most life-threatening complication of portal hypertension and its primary treatment is medical according to the Baveno VII guidelines. This review discusses the evidence on surgical portal decompression for adult patients with NCPH secondary to chronic extrahepatic portal vein obstruction (EHPVO).
View Article and Find Full Text PDFThe Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review.
J Clin Med
January 2025
Abdominal Surgery and Phlebology Research Center, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Anlotinib, a novel multi-kinase inhibitor targeting angiogenesis and tumor proliferation pathways, has shown promising efficacy in various cancers. Its role in treating thyroid cancer, particularly radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), is of significant clinical interest. This systematic review aims to evaluate the efficacy and safety of Anlotinib in patients with thyroid cancer, analyzing outcomes such as progression-free survival (PFS), overall survival (OS), response rates, and adverse events.
View Article and Find Full Text PDF[Clinical application of multidisciplinary team in the diagnosis and treatment of chronic refractory wounds].
Beijing Da Xue Xue Bao Yi Xue Ban
February 2025
Department of Orthopedics, Peking University Third Hospital, Beijing 100191, China.
Objective: To explore the application effectiveness of multidisciplinary team (MDT) in the diagnosis and treatment of chronic refractory wounds, and to provide new ideas for optimizing the clinical diagnosis and treatment of such diseases.
Methods: A retrospective analysis was performed on the clinical data of patients with chronic refractory wounds who underwent surgery at Peking University Third Hospital from January 2015 to October 2023, and a total of 456 patients, including 290 males and 166 females, with an average age of (49.4±16.
Recurrent Portal Hypertension after Liver Transplant: Impact on Survival and the Role of TIPS Creation in Management.
J Vasc Interv Radiol
January 2025
Mallinckrodt Institute of Radiology, Washington University, Vascular and Intrventional Radiology. Electronic address:
Introduction: Recurrent portal hypertension (PH) after liver transplant (LT) and its management are not well-studied. This study aims to evaluate the impact of transjugular intrahepatic portosystemic shunt (TIPS) on outcomes of recurrent PH.
Methods: From a cohort of 1846 LT recipients, 36 patients who underwent TIPS creation after LT were identified and considered as cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!